Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report the clinical features and outcome of 16 patients with cryoglobulinaemia. Two patients with Type I cryoglobulinaemia both had IgG kappa monoclonal paraproteins. Nine of 10 with Type II disease had monoclonal IgM kappa and polyclonal IgG; one had monoclonal IgG kappa and polyclonal IgG in the cryoglobulin. Underlying disorders identified in 3 of the 4 Type III patients were Sjogren's syndrome, infective endocarditis, and non-A non-B hepatitis and HTLV III infection. The commonest presenting features were rash in 94 p. 100 (ulceration 25 p. 100), arthralgia in 63 p. 100 (erosive arthritis 32 p. 100), renal disease in 63 p. 100, neurological involvement in 56 p. 100, hepatomegaly in 32 p. 100 and splenomegaly in 32 p. 100. Major associated conditions were progressive bronchiectasis in one case, and severe peripheral vascular disease in another; underlying malignancy was found in 2 cases (lymphoma and malignant melanoma). Treatment was with plasma exchange (PE) and immunosuppressive drugs (ID) in 10, PE alone in 3, ID alone in 2 and antibiotics [corrected] in 1. Fourteen of 16 patients showed an initial clinical response and fall in cryoglobulin levels. Four patients have died, one each from gastro-intestinal haemorrhage, sepsis, pulmonary embolism and lymphoma. Of the remaining 12 patients, all are symptomatically controlled and 10 have persisting cryoglobulinaemia (3 on PE and ID, 2 on PE, 2 on ID and 3 on no treatment). Of the two cases in whom cryoglobulinaemia resolved, one (Type II) had received PE and ID and the other (Type III) had been treated with antibiotics and surgery for infective endocarditis.
 ...
PMID:Cryoglobulinaemia: clinical features and response to treatment. 376 96

In a study designed to show whether purulent bronchial secretions damage the lung reversibly or irreversibly, 18 patients with bronchiectasis underwent lung function tests before and after two weeks' antibiotic treatment to convert their sputum from purulent to mucoid, and 10 of them also after four months' treatment. After two weeks FEV1, forced vital capacity, vital capacity, functional residual capacity, and total lung capacity showed small but statistically significant (though not clinically useful) improvements. In the 10 patients studied after four months only FVC (of the four indices with significant improvements at two weeks in this group) was still higher than before treatment. These results contrast with those of an earlier study, in which large acute changes were found, perhaps because of differences in the patients studied. It is concluded that the absence of major changes in lung function points to physiological abnormality that is largely irreversible in these patients with chronic bronchial sepsis.
 ...
PMID:Effect of short and long term antibiotic response on lung function in bronchiectasis. 378 11

Biweekly 200 mg/kg infusions of immune globulin (Gamimune) were given to a 46-year-old woman with severe common variable immunodeficiency, bronchiectasis, and chronic diarrhea with malabsorption. Failure to achieve therapeutically effective serum IgG concentrations in the face of fulminant sepsis was accompanied by a shortened serum IgG half-life of 10.6 days. Currently recommended doses of 200 mg/kg may prove inadequate in very ill patients with sepsis and malabsorption.
 ...
PMID:Intravenous immune globulin therapy. Treatment of a patient with severe immunodeficiency, chronic malabsorption, and fulminant septicemia. 392 22

Three grams of amoxycillin administered twice daily for seven days, as an oral powder (Amoxil 3G sachets, Bencard) dispersed in water, to 17 patients with bronchiectasis resulted in striking clinical, spirometric and bacteriological improvement in 11 of 12 patients who were producing purulent sputum from which Haemophilus influenzae was cultured by a selective bacteriological technique (Roberts & Cole, 1980). In the five patients from whose sputum this organism could not be cultured, and in one from whom it could, there was no improvement. Untoward effects were limited to nausea in one patient and acceptability of the regimen by the remaining patients was unanimous. There was no evidence of accumulation of the drug in serum or sputum. The rapidity of effect and oral form of the treatment suggest that it may provide a simple out-patient regimen for chronic bronchial sepsis and severe purulent exacerbations of chronic bronchitis from which H. influenzae can be cultured.
 ...
PMID:A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae. 660 Nov 2

We report here our first experience with the use of a total artificial heart in a human being. The heart was developed at the University of Utah, and the patient was a 61-year-old man with chronic congestive heart failure due to primary cardiomyopathy, who also had chronic obstructive pulmonary disease. Except for dysfunction of the prosthetic mitral valve, which required replacement of the left-heart prosthesis on the 13th postoperative day, the artificial heart functioned well for the entire postoperative course of 112 days. The mean blood pressure was 84 +/- 8 mm Hg, and cardiac output was generally maintained at 6.7 +/- 0.8 liters per minute for the right heart and 7.5 +/- 0.8 for the left, resulting in postoperative diuresis and relief of congestive failure. The postoperative course was complicated by recurrent pulmonary insufficiency, several episodes of acute renal failure, episodes of fever of unidentified cause (necessitating multiple courses of antibiotics), hemorrhagic complications of anticoagulation, and one generalized seizure of uncertain cause. On the 92nd postoperative day, the patient had diarrhea and vomiting, leading to aspiration pneumonia and sepsis. Death occurred on the 112th day, preceded by progressive renal failure and refractory hypotension, despite maintenance of cardiac output. Autopsy revealed extensive pseudomembranous colitis, acute tubular necrosis, peritoneal and pleural effusion, centrilobular emphysema, and chronic bronchitis with fibrosis and bronchiectasis. The artificial heart system was intact and uninvolved by thrombosis or infectious processes. This experience should encourage further clinical trials with the artificial heart, but we emphasize that the procedure is still highly experimental. Further experience, development, and discussion will be required before more general application of the device can be recommended.
 ...
PMID:Clinical use of the total artificial heart. 1476 80

During the ten years 1972 to 1981, 16 patients with persistent bronchopleural fistulas were treated. Eleven patients had postoperative fistulas, and five had fistulas which were spontaneous in origin. The spontaneous fistulas were due to tuberculosis (three) and lung abscess (two). The postoperative bronchopleural fistulas occurred after pulmonary resections for cancer (six), aspergillosis (three) and bronchiectasis (two). All of the postoperative fistulas developed in patients in whom the nonresected lung failed to fill the pleural cavity. The pneumothorax space then became infected, and breakdown of the sutured bronchus followed. Two patients died before any surgical intervention could be carried out. Two patients had successful resuture of a leaking bronchial stump two and eight days after their initial operation. Two healed after prolonged chest tube drainage. In ten patients, a thoracoplasty was required before closure of the fistula was accomplished. One of these patients died eight weeks postoperatively of sepsis involving the other lung.
 ...
PMID:Management of bronchopleural fistulas. 670 40

Micronomicin sulfate (MCR) by intravenous drip infusion for internal field infections was studied in 30 cooperative research institutions and the following results were obtained. Clinical efficacy of MCR on respiratory tract infections was 79.4% for pneumonia, 51.5% for chronic bronchitis and 81.0% for respiratory tract infections associated with bronchiectasis, respectively, with a total effectiveness rate of 70.9%. MCR was effective on urinary tract infections with a rate of 85% and on septicemia with a rate of 80%. There were no cases of clinical symptoms seemed to be adverse reactions. Abnormal laboratory test values were noted in 13 out of 167 cases (7.8%), but all of them were transient without severe reactions observed. It is fully expected that MCR intravenous drip infusion for internal field infection is clinically effective.
 ...
PMID:[Clinical studies of intravenous drip infusion of micronomicin. Internal field infections]. 672 32

Wegener's granulomatosis was diagnosed in a 42-year-old female 16 years ago. From the outset there was upper respiratory, pulmonary, and renal involvement. Over the years she received varying combinations of glucocorticoids and azathioprine. Renal function deteriorated, and she was treated by hemodialysis and living related donor transplantation 9 and 10 years, respectively, after the onset of the disease. 3 months prior to transplantation, the patient had a right pneumonectomy for bronchial stenosis, bronchiectasis and repeated sepsis. 5 years' posttransplantation, she is well and has no signs of activity of original disease.
 ...
PMID:Wegener's granulomatosis: prolonged patient survival after pneumonectomy and renal transplantation. 676 94

A case of broncho-oesophageal fistula causing bronchiectasis of the left lung is reported. Oesophagorespiratory fistulas without atresia of the oesophagus often have an insidious clinical course and most commonly present in adulthood. This rare congenital anomaly should be considered as a cause of chronic pulmonary sepsis. The clinical, radiographic and therapeutic features of this lesion are discussed.
 ...
PMID:Congenital broncho-oesophageal fistula. A case report. 684 53

Bronchopulmonary infections with Aspergillus give rise to three different pathological entities. Allergic bronchopulmonary aspergillosis, found in patients with an atopic predisposition, is marked by dyspnea of the asthmatic type associated with labile radiologically detectable infiltrates, blood hypereosinophilia, enhanced total IgE levels, specific IgG fractions, and positive immediate reactions to skin tests. The long-term risk is the development of proximal bronchiectasis. Dosage and duration of corticotherapy are function of eosinophilia and total IgE levels. Pathogenicity is similar to that of extrinsic allergic alveolitis, probably involving disturbances in immune complexes from a type I reaction. Intracavital pulmonary aspergillosis involves mycotic development within a cavity or a complicating parenchymatous lesion. Severe hemoptysis may occur. Medical treatment is ineffective, and radical surgery is necessary in patients able to support operative procedures, which vary as a function of the condition of the patient. Diffuse aspergillosis occurs in immunodeficient patients, usually during the acute phase of chemotherapy induction. Spread of the disease is either from the upper respiratory tract or through the blood as septicemia. A nosocomial origin is frequent. Diagnosis depends more on the presence of hyphae in tissue biopsy specimens than cultures or serological tests which are too unreliable. Treatment is with amphotericin B preferably associated with 5 fluorocytosin.
 ...
PMID:[Bronchopulmonary aspergillosis (author's transl)]. 708 69


<< Previous 1 2 3 4 5 Next >>